Background:The measurement of circulating tumor DNA(ctDNA)has been studied in several malignancies,including metastatic pancreatic cancer,but less is known about its utility in monitoring treatment response and recurr...Background:The measurement of circulating tumor DNA(ctDNA)has been studied in several malignancies,including metastatic pancreatic cancer,but less is known about its utility in monitoring treatment response and recurrence in resectable pancreatic cancer.Methods:We conducted a systematic review of the literature examining the association of ctDNA with overall survival(OS)and disease-free survival.Results:Five articles met our exclusion criteria.Baseline and/or postoperative ctDNA was found to be associated with decreased OS and recurrence-free survival.Discussion:ctDNA has the potential to be used as a prognostic biomarker and to guide therapy in resectable pancreatic cancer.展开更多
文摘Background:The measurement of circulating tumor DNA(ctDNA)has been studied in several malignancies,including metastatic pancreatic cancer,but less is known about its utility in monitoring treatment response and recurrence in resectable pancreatic cancer.Methods:We conducted a systematic review of the literature examining the association of ctDNA with overall survival(OS)and disease-free survival.Results:Five articles met our exclusion criteria.Baseline and/or postoperative ctDNA was found to be associated with decreased OS and recurrence-free survival.Discussion:ctDNA has the potential to be used as a prognostic biomarker and to guide therapy in resectable pancreatic cancer.
